Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis.
about
Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive ratsMagnetic resonance imaging and multi-detector computed tomography assessment of extracellular compartment in ischemic and non-ischemic myocardial pathologiesSimvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathyReversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic ratsAldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathyPhenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation.A transgenic rabbit model for human hypertrophic cardiomyopathy.Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction.Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia.Adhesion proteins, stem cells, and arrhythmogenesis.Modifier genes for hypertrophic cardiomyopathyMicrotopographical effects of natural scaffolding on cardiomyocyte function and arrhythmogenesis.Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo.Histomorphometric evaluation of the small coronary arteries in rats exposed to industrial noiseAmeliorative effects of Xue-Fu-Zhu-Yu decoction, Tian-Ma-Gou-Teng-Yin and Wen-Dan decoction on myocardial fibrosis in a hypertensive rat mode.Conditional lineage ablation to model human diseases.Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluationTemporal and morphological impact of pressure overload in transgenic FHC mice.Atrial fibrillation and heart failure: cause or effect?Magnetic resonance imaging for characterizing myocardial diseases.Effect of U50,488H, a κ-opioid receptor agonist on myocardial α-and β-myosin heavy chain expression and oxidative stress associated with isoproterenol-induced cardiac hypertrophy in rat.Comparison of left atrial electrophysiologic abnormalities during sinus rhythm in patients with different type of atrial fibrillation.l-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats.Scar homogenization in AF ablation: Evolution and practice.Gualou Xiebai Decoction prevents myocardial fibrosis by blocking TGF-beta/Smad signalling.Serum level of transforming growth factor beta 1 is associated with left atrial voltage in patients with chronic atrial fibrillation.Cardiac magnetic field map topology quantified by Kullback-Leibler entropy identifies patients with hypertrophic cardiomyopathy.Cardiac FKBP12.6 overexpression protects against triggered ventricular tachycardia in pressure overloaded mouse hearts.The Development of Serum Amyloid P as a Possible Therapeutic
P2860
Q24673267-22BB5AA3-2829-4E4A-9673-3B5E07FAC4AFQ26824231-0012C4CE-1B14-4C86-9D07-0E90005BECF7Q28344111-CFD6A3F3-7E4E-44C7-BA3B-A3AC1CD2235AQ28367881-23D8CA8A-82C4-48D8-856E-70D5B67603C6Q28570951-E915C7A4-0897-48E1-A087-E261ECE9358BQ30384457-6AA7A5C5-1689-4A71-97DA-5F928E65FB4EQ33903354-2DB7EC50-F22D-4F6D-B4E8-868FD2E08512Q34021080-62B4C041-B346-4F04-8035-C9B822E2A1FBQ34043095-E25EB92A-3218-43C4-9421-DF29C4E7A11BQ34195775-00DF7D2A-EE6B-4D50-A2CF-56185F280A8CQ34477403-46307F82-000A-437B-9BB7-9F31A2E8962EQ34641881-CB4DF21E-CACB-45F2-BE1F-38D3F58E64C4Q34987926-ED2D6AA5-B6D2-4630-83D4-D94E367EBA8FQ35110788-3F361FDD-0E1F-4388-B502-830BFCA06C80Q35723174-D44D7600-0062-4B6E-A541-94B81BB32ECEQ35916617-1529D0BC-D621-4C1A-A4CA-1407C0677C28Q36310580-1736FA52-C425-4A51-BB4F-9E95443FD08EQ36366148-AC169E6F-538A-4C94-A420-A27A803DA095Q37121496-719DB447-1016-465E-9BD2-21C6DC56334DQ38254552-10FE0435-2959-4455-9DB9-0854C85A424DQ38736889-BDB3C309-7F6B-4DFA-8926-6B6EAEEF9ABAQ42929638-451AB6BB-D0D9-4ADC-94EB-C14671118F90Q45370292-2C1BA6DC-DFA5-46F8-B9FC-052B97E4B3A9Q46516449-95F8E42C-92AF-4604-A4BD-0B45DA672DAAQ47127645-94DD4D83-89EB-4069-A8CE-7E53358CEC38Q47828229-DED477B1-053E-4C21-ABE9-52E60A94B211Q49864738-0DB37750-D1D3-49EF-AAF1-98F1E203EB0BQ51918098-1674122E-BD66-4145-BDE5-718E23B7C41AQ54325373-86596D49-50D8-4159-AFC3-D474545D3825Q59136382-75E910AA-56A4-4A34-95D2-820B7486E034
P2860
Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Compensated cardiac hypertroph ...... ardial phenotype. I. Fibrosis.
@en
type
label
Compensated cardiac hypertroph ...... ardial phenotype. I. Fibrosis.
@en
prefLabel
Compensated cardiac hypertroph ...... ardial phenotype. I. Fibrosis.
@en
P2093
P1476
Compensated cardiac hypertroph ...... ardial phenotype. I. Fibrosis.
@en
P2093
Chevalier B
Delcayre C
Swynghedauw B
P304
P356
10.1016/S0008-6363(97)00073-4
P577
1997-06-01T00:00:00Z